This is a clinical validation milestone for Nociscan but lacks financial details. Monitor for trial enrollment updates and potential future commercial expansion. Given ACON's $8M market cap and history of neutral filings with limited stock movement, this is unlikely to be a near-term catalyst.
Price Chart
Executive Summary
Aclarion announced a second commercial agreement with Weill Cornell Medicine for a prospective randomized controlled trial evaluating Nociscan's role in lumbar microdiscectomy surgery with BMAC injections. This is a positive clinical validation step but has no immediate revenue impact for a micro-cap company with an $8M market cap.
Key Facts
- Second trial agreement with Weill Cornell Medicine to use Nociscan in a prospective randomized controlled trial
- Trial evaluates lumbar microdiscectomy surgery with/without intradiscal BMAC injection over 2 years
- Led by renowned neurosurgeon Roger Härtl, MD, who serves as a paid consultant for Aclarion
- Chronic low back pain affects ~266M people worldwide
- Nociscan claims 97% surgical success rate when all pain-positive discs are treated
- No financial terms or revenue projections disclosed in the press release
Financial Impact
No financial terms disclosed; agreement is a clinical trial collaboration with no immediate revenue
Risk Factors
- Trial results may not support Nociscan's clinical utility or commercial adoption
- No revenue or financial commitment disclosed; agreement may not lead to material revenue
- Micro-cap stock with low liquidity and high volatility; limited analyst coverage
- Paid consultant relationship with Dr. Härtl introduces potential bias in trial outcomes
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3287438 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 19, 2026 9w ago | Insider Cluster | $2.77 $2.64 | ▼ −4.69% | ▼ −2.74% | $1.92 (−30.69%) |
Aug 18, 2026 10w ago | Insider Cluster | $2.60 $2.53 | ▼ −2.67% | ▼ −1.68% | $1.92 (−26.15%) |
Jun 9, 2026 20w ago | Press Release | $3.26 $2.99 | ▼ −8.28% | ▼ −9.73% | $1.92 (−41.10%) |
Jun 8, 2026 20w ago | Press Release | $3.36 $3.07 | ▼ −8.63% | ▼ −10.26% | $1.92 (−42.86%) |
Jun 3, 2026 20w ago | Press Release | $3.49 $3.09 | ▼ −11.46% | ▼ −10.46% | $1.92 (−44.99%) |
Jun 1, 2026 21w ago | Press Release | $3.37 $2.88 | ▼ −14.54% | ▼ −13.24% | $1.92 (−43.03%) |
May 6, 2026 24w ago | Insider Cluster | $3.28 $3.49 | ▲ +6.40% | ▲ +3.62% | $1.92 (−41.46%) |
May 5, 2026 25w ago | Press Release | $3.20 $3.50 | ▲ +9.38% | ▲ +4.42% | $1.92 (−40.00%) |
Apr 22, 2026 26w ago | Press Release | $3.73 $3.20 | ▼ −14.21% | ▼ −17.37% | $1.92 (−48.53%) |
Mar 19, 2026 31w ago | Press Release | $3.26 $3.39 | ▲ +3.99% | ▼ −3.63% | $1.92 (−41.10%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers